Regeneron says its COVID-19 antibody drug lowers infection risk by 81%

Regeneron Pharmaceuticals on Monday said its COVID-19 antibody drug reduced the risk of symptomatic infections by 81 percent in a phase-three trial of the therapy.

The company said it will ask the U.S. Food and Drug Administration (FDA) to allow its antibody therapy to be used as a preventative treatment for COVID-19.